According to a new report by Polaris Market Research, the global pneumococcal vaccine market was valued at USD 9.16 billion in 2025 and is projected to reach USD 14.57 billion by 2034, expanding at a CAGR of 5.30% over the forecast period. Growth is underpinned by rising incidence of pneumococcal disease across age groups, expanding government-backed immunization programs, and accelerating innovation in higher-valency vaccine platforms across pediatric and adult end-use segments.

What Is Driving Pneumococcal Vaccine Market Growth?

Demand is climbing as the rising global burden of pneumococcal disease converges with health policies that promote widespread vaccination. Governments and healthcare providers are prioritizing immunization coverage, pushing pneumococcal vaccine adoption across both pediatric programs and expanding adult eligibility criteria. Polaris analysts note that North America's 40.9% revenue share in 2025 positions the region for continued leadership through the forecast period, while Asia Pacific is set to post the fastest incremental gains, growing at a 6.8% CAGR as investment in regional vaccine development accelerates.

Key Trends Shaping the Pneumococcal Vaccine Industry

Advancing Toward Higher-Valency, Next-Generation Vaccines

The industry is moving beyond 13-valent formulations toward 15-, 20-, and 21-valent conjugate vaccines that cover a broader range of Streptococcus pneumoniae serotypes. Pfizer's approval of Prevnar 20 for adults, Merck's late-stage 21-valent V116 candidate, and a Sanofi–SK Bioscience collaboration on next-generation conjugate vaccines all point to a wave of product innovation aimed at closing serotype gaps left by earlier formulations.

Expanding Immunization Policy and Regulatory Support

Regulatory bodies are accelerating review timelines, and public health guidance is widening eligibility. The U.S. CDC's Advisory Committee on Immunization Practices lowered the recommended age for adult PCV vaccination from 65 to 50, while GAVI-supported programs pushed third-dose PCV coverage in member countries from 56% to 70% between 2019 and 2022, reflecting the industry's regulatory and public-health tailwinds.

Cost-Efficiency and Broader Market Access

Pricing and affordability continue to shape uptake, particularly in cost-conscious markets. Products such as Synflorix are gaining traction in budget-constrained regions due to their favorable cost profile, while national programs — including Indonesia's 2022 nationwide PCV rollout — illustrate how affordability initiatives are widening access and supporting sustained market expansion.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/pneumococcal-vaccine-market  

Market Segmentation: Breaking Down the Pneumococcal Vaccine Market

Polaris segments the pneumococcal vaccine market by vaccine type, product, end user, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Vaccine Type

The pneumococcal polysaccharide vaccine (PPV) segment led the market in 2025, accounting for 54.6% of revenue, on the strength of its broad multi-strain coverage and established use in older adults with underlying health conditions. The pneumococcal conjugate vaccine (PCV) segment is projected to expand at the fastest CAGR of 7.2% through 2034 as advanced conjugate formulations deliver stronger, longer-lasting immune protection and broader serotype coverage.

By Product

Prevnar 13 remains widely used given its established regulatory approvals across infant, adult, and pediatric populations. The Synflorix segment is projected to register the fastest CAGR of 7.6% through the forecast period, driven by its cost-effectiveness and growing penetration in developing regions where budget constraints shape purchasing decisions.

By End User

Among end users, the public sector captured the larger share of pneumococcal vaccine demand, reflecting the central role of national immunization schedules and GAVI-supported programs in driving bulk procurement. The private sector continues to grow steadily, supported by adult and geriatric vaccination through hospital and pharmacy channels.

By Program Type

Childhood immunization programs remain the single largest driver of volume, given the World Health Organization's estimate that pneumococcal disease causes roughly 1.6 million deaths annually, including up to 1 million among children under five. Adult and geriatric immunization is emerging as the fastest-growing program category as expanded age eligibility and shared clinical decision-making between physicians and patients broadens the addressable population.

Regional Outlook: Where Is the Pneumococcal Vaccine Market Growing Fastest?

North America led the market in 2025 on the back of strong healthcare infrastructure, early vaccine adoption, and a steady stream of FDA approvals, including Pfizer's 20-valent Prevnar 20. Asia Pacific is expected to post the fastest CAGR through 2034, driven by rising investment in vaccine development, a rapidly expanding population, and increasing incidence of pneumococcal infections. Within North America, the U.S. remains the largest single market; within Asia Pacific, expanding biopharmaceutical R&D investment is the primary growth engine. Europe rounds out the leading regions, supported by well-established public immunization infrastructure.

Competitive Landscape: Leading Pneumococcal Vaccine Companies

Key players profiled in the report include GSK plc, Pfizer Inc., Merck KGaA, Serum Institute of India, CSL Ltd., Sanofi S.A., Walvax Biotechnology, Beijing Minhai Biotechnology, Johnson & Johnson, AstraZeneca, and Novavax, who are focusing on next-generation product launches, strategic collaborations, and manufacturing-cost reduction to strengthen market position across the PPV and pediatric immunization segments outlined above. Recent moves include Pfizer's advancement of a 25-valent pediatric candidate into Phase 3 trials and Merck's STRIDE-10 data readout for its 21-valent V116 candidate, both aimed at deepening share in North America and Europe.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the pneumococcal vaccine market, this report benchmarks market share, segment-level pricing, and forecast data — by vaccine type, product, end user, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking next-generation, higher-valency vaccines as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Extracellular Matrix Patches Market

Cedarwood Oil Market

Offshore Decommissioning Market

Linseed Oil Market

Canola Oil Market

Canola Oil Market

Pumpkin Seeds Market

Surgical Planning Software Market

Decorative Laminates Market